JP2023537222A5 - - Google Patents
Info
- Publication number
- JP2023537222A5 JP2023537222A5 JP2023503448A JP2023503448A JP2023537222A5 JP 2023537222 A5 JP2023537222 A5 JP 2023537222A5 JP 2023503448 A JP2023503448 A JP 2023503448A JP 2023503448 A JP2023503448 A JP 2023503448A JP 2023537222 A5 JP2023537222 A5 JP 2023537222A5
- Authority
- JP
- Japan
- Prior art keywords
- superantigen
- cancer
- superantigen conjugate
- conjugate according
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063053859P | 2020-07-20 | 2020-07-20 | |
| US63/053,859 | 2020-07-20 | ||
| PCT/IL2021/050882 WO2022018726A1 (en) | 2020-07-20 | 2021-07-20 | Superantigen conjugate for use in methods and compositions for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023537222A JP2023537222A (ja) | 2023-08-31 |
| JP2023537222A5 true JP2023537222A5 (https=) | 2024-07-24 |
Family
ID=79728646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023503448A Pending JP2023537222A (ja) | 2020-07-20 | 2021-07-20 | 癌を治療するための方法および組成物における使用のためのスーパー抗原コンジュゲート |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230285588A1 (https=) |
| EP (1) | EP4181965A4 (https=) |
| JP (1) | JP2023537222A (https=) |
| KR (1) | KR20230085904A (https=) |
| CN (1) | CN116490521A (https=) |
| AU (1) | AU2021313881A1 (https=) |
| CA (1) | CA3173909A1 (https=) |
| IL (1) | IL299950A (https=) |
| WO (1) | WO2022018726A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| CN120847420B (zh) * | 2025-09-23 | 2025-12-02 | 天津医科大学总医院 | T细胞亚群在制备评估b细胞耗竭疗法试剂盒中的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003061694A1 (en) * | 2001-05-10 | 2003-07-31 | Seattle Genetics, Inc. | Immunosuppression of the humoral immune response by anti-cd20 antibodies |
| SE0102327D0 (sv) * | 2001-06-28 | 2001-06-28 | Active Biotech Ab | A novel engineered superantigen for human therapy |
| KR20250071286A (ko) * | 2016-01-10 | 2025-05-21 | 네오티엑스 테라퓨틱스 엘티디. | 면역강화제에 의해 증진되는 초항원 매개된 암 면역요법 |
-
2021
- 2021-07-20 IL IL299950A patent/IL299950A/en unknown
- 2021-07-20 JP JP2023503448A patent/JP2023537222A/ja active Pending
- 2021-07-20 AU AU2021313881A patent/AU2021313881A1/en active Pending
- 2021-07-20 KR KR1020237005638A patent/KR20230085904A/ko not_active Withdrawn
- 2021-07-20 WO PCT/IL2021/050882 patent/WO2022018726A1/en not_active Ceased
- 2021-07-20 EP EP21846878.3A patent/EP4181965A4/en active Pending
- 2021-07-20 CA CA3173909A patent/CA3173909A1/en active Pending
- 2021-07-20 CN CN202180064210.5A patent/CN116490521A/zh active Pending
- 2021-07-20 US US18/006,243 patent/US20230285588A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023537222A5 (https=) | ||
| TWI786044B (zh) | 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法 | |
| Guo et al. | Phase 1b/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases | |
| US10232040B2 (en) | Anti-B7 H1 and anti-CTLA-4 antibodies for treating non-small cell lung cancer | |
| WO2019140150A1 (en) | Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer | |
| JP2023548051A (ja) | 肺がんのためのｌａｇ－３アンタゴニスト療法 | |
| WO2022174775A1 (en) | Use of antibody-drug conjugate targeting her2 in treatment of specific breast cancer | |
| Huet et al. | Targeted nanofitin-drug conjugates achieve efficient tumor delivery and therapeutic effect in an EGFRpos mouse xenograft model | |
| WO2024184349A1 (en) | Antitumor combinations containing anti-ceacam5 antibody-drug conjugates, anti-vegfr-2 antibodies and anti-pd1/pd-l1 antibodies | |
| JP2023011902A (ja) | Ｐｄ－１阻害剤を投与することにより子宮頸がんを処置する方法 | |
| JP2024519907A (ja) | 尿路上皮癌の治療における、免疫チェックポイント阻害剤と併用での抗体薬物複合体の使用 | |
| JP2025542297A (ja) | 肺癌の組み合わせ療法 | |
| AU2024286132A1 (en) | Antitumor combinations containing anti-ceacam5 antibody-drug conjugates, anti-pd1/pd-l1 antibodies and anti-ctla4 antibodies | |
| US20230061858A1 (en) | Treatment with site specific her2 antibody-drug conjugates | |
| Andratschke et al. | Biodistribution and radioimmunotherapy of SCCHN in xenotransplantated SCID mice with a 131I-labelled anti-EpCAM monoclonal antibody | |
| RU2833461C1 (ru) | Способы лечения рака шейки матки путем введения инибитора pd-1 | |
| Wang et al. | Precise regulation of cancer vaccine and immune checkpoint inhibitor synergy potentiates immunotherapy with reduced immune-related pneumonitis | |
| Toldrà et al. | American Association for Cancer Research (AACR)-113th Annual Meeting. New Orleans/Virtual-April 8-13, 2022 | |
| WO2026039321A1 (en) | Methods for treating prostate cancer | |
| Teicher | Antibody drug and radionuclide conjugates for GI cancers | |
| WO2025256641A1 (zh) | 抗pd-l1抗体和抗ctla-4抗体联合治疗肿瘤 | |
| WO2025078686A1 (en) | Combination therapy involving antibody-drug conjugates against claudin18.2 and pd1/pd-l axis inhibitors for treatment of cancer | |
| EP4297782A1 (en) | Methods of treating lung cancer by administering a pd-1 inhibitor | |
| WO2026046410A1 (zh) | 一种抗体药物偶联物与免疫检查点抑制剂的组合 | |
| WO2025252203A1 (zh) | 抗Nectin-4抗体药物偶联物治疗肿瘤的用途 |